ImmuPharma plc (LON:IMM – Get Free Report) shares were down 6.4% during trading on Wednesday . The company traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.40 ($0.05). Approximately 3,579,628 shares traded hands during trading, a decline of 82% from the average daily volume of 19,977,498 shares. The stock had previously closed at GBX 4.70 ($0.06).
ImmuPharma Stock Performance
The company has a 50 day simple moving average of GBX 2.60 and a two-hundred day simple moving average of GBX 1.99. The firm has a market cap of £18.45 million, a PE ratio of -443.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- How to Profit From Growth Investing
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- 3 Small Caps With Big Return Potential
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Why Are These Companies Considered Blue Chips?
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
